Jade Biosciences (JBIO) Total Non-Current Liabilities (2021 - 2025)

Jade Biosciences (JBIO) has 5 years of Total Non-Current Liabilities data on file, last reported at $2.4 million in Q1 2025.

• Quarterly Total Non-Current Liabilities fell 84.75% year-over-year to $2.4 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.4 million (down 84.75% YoY) and the FY2024 annual result came in at $12.0 million, down 32.95% from the prior year.
• Total Non-Current Liabilities retreated to $2.4 million in Q1 2025, from $12.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $17.9 million in Q4 2023 to a low of $2.4 million in Q1 2025.
• A 5-year average of $10.4 million and a median of $10.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 197.96% — and 2025, when it plunged 84.75%.
• Tracing JBIO's Total Non-Current Liabilities over 5 years: stood at $2.9 million in 2021, then surged by 189.46% to $8.5 million in 2022, then jumped by 110.82% to $17.9 million in 2023, then plunged by 32.95% to $12.0 million in 2024, then tumbled by 79.85% to $2.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $2.4 million (Q1 2025), $12.0 million (Q4 2024), and $10.4 million (Q3 2024), per Business Quant data.